id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2025-E-0362-0006,FDA,FDA-2025-E-0362,Determination of Regulatory Review Period for Purposes of Patent Extension; AUCATZYL,Notice,Determinations,2026-02-13T05:00:00Z,2026,2,2026-02-13T05:00:00Z,2026-04-15T03:59:59Z,2026-02-13T20:01:58Z,2026-02972,1,0,09000064b91a9ffe
FDA-2025-E-0362-0005,FDA,FDA-2025-E-0362,Letter to U.S. Patent and Trademark Office,Other,Letter(s),2025-12-02T05:00:00Z,2025,12,2025-12-02T05:00:00Z,,2025-12-03T02:27:03Z,,0,0,09000064b90aac5c
FDA-2025-E-0362-0004,FDA,FDA-2025-E-0362,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2025-11-05T05:00:00Z,2025,11,2025-11-05T05:00:00Z,,2025-11-05T22:12:21Z,,0,0,09000064b90691a4
FDA-2025-E-0362-0003,FDA,FDA-2025-E-0362,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2025-09-26T04:00:00Z,2025,9,2025-09-26T04:00:00Z,,2025-11-05T17:15:18Z,,0,0,09000064b8fdef5a
FDA-2025-E-0362-0002,FDA,FDA-2025-E-0362,"Patent Extension Application from Marshall, Gerstein & Borun, LLP (on behalf of Autolus Limited)",Other,Application,2025-02-04T05:00:00Z,2025,2,2025-02-04T05:00:00Z,,2025-02-04T18:29:35Z,,0,0,090000648691b82c
FDA-2025-E-0362-0001,FDA,FDA-2025-E-0362,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2025-02-04T05:00:00Z,2025,2,2025-02-04T05:00:00Z,,2025-02-04T18:29:28Z,,0,0,090000648691b82a